Complement C7 ELISA Kit

$1,525.00

The C7 ELISA Kit is intended for the quantitative determination of complment C7 in serum and plasma samples. The C7 ELISA Kit is for research use only and not to be used for diagnostic procedures.

Complement C7 ELISA Kit

Complement component C7 is an essential protein of the terminal complement pathway and plays a critical role in the formation of the terminal complement complex (TCC), also known as the membrane attack complex (MAC). Following cleavage of C5 by C5 convertase, C5b binds C6 and subsequently recruits C7 to form the C5b-7 complex. This interaction induces a conformational change in C7, transitioning it from a hydrophilic to an amphiphilic state that allows the complex to associate with target cell membranes. Subsequent binding of C8 and polymerization of C9 complete MAC assembly, resulting in the formation of the C5b-9 complex. The membrane-bound MAC can disrupt cellular membrane integrity, leading to cell lysis, or trigger cellular signaling and inflammatory responses. C7 is also produced by immune cells, including polymorphonuclear leukocytes, and may contribute to localized complement activity during inflammation.

In research settings, C7 is studied for its role in terminal complement activation, immune regulation, and inflammatory processes. Genetic variation in C7, including polymorphisms associated with different protein allotypes, may influence complement function and individual immune responses. The C7 M allotype, identified using the monoclonal antibody WU 4-15, represents one example of C7 protein variation. C7 has also attracted research interest in neurodegenerative diseases, particularly Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). Studies have investigated associations between C7 genetic variation, including the rs3792646 (p.K420Q) missense variant, and Alzheimer’s disease-related characteristics such as disease onset, progression, hippocampal volume, and working memory. Complement proteins, including C7, are also being investigated for their potential involvement in neuronal viability, amyloid-beta processing, synaptic function, and neuroinflammation.

In clinical research, C7 is investigated as a potential biomarker of terminal complement pathway activity and complement-associated disease processes. Alterations in C7 expression or concentration may provide insight into complement dysregulation in neurodegenerative and inflammatory conditions. Research has also suggested a possible association between reduced C7 levels, altered complement activity, and active Long COVID, although further investigation is needed to establish the clinical significance of these findings. Measurement of C7 can help researchers evaluate terminal complement pathway activity and investigate its contribution to inflammatory responses, immune dysfunction, and disease progression. However, C7 concentration alone does not establish MAC formation or functional complement activity, and results should be interpreted alongside other complement components and functional measurements.

This Complement C7 ELISA Kit is manufactured in Netherlands by Hycult Biotech.

Size
Sensitivity 1.56 ng/mL
Dynamic Range 1.56 -100 ng/mL
Incubation Time 1 hour 15 minutes
Sample Type Serum, Plasma
Storage 2-8°C
Alternative Names Complement Component C7, Complement C7

 

Product Citations